Recent Event

2022 Annual Meeting of Stockholders

Latest Financial Results

Latest Annual Report

For Fiscal Year Ending Dec 31, 2021

mail icon

Sign Up for Email Alerts

Receive updates straight into your inbox

Sign up today

Company Overview

Pieris is a clinical-stage biotechnology company that combines leading protein engineering capabilities and deep understanding into molecular drivers of disease to develop medicines that drive local biology to produce superior clinical outcomes for patients. Our pipeline includes inhalable Anticalin proteins to treat respiratory diseases and locally-activated bispecifics for immuno-oncology. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by respiratory and immuno-oncology focused partnerships with leading pharmaceutical companies.

Investor Contact Information


Pieris Pharmaceuticals, Inc.
255 State Street, 9th floor
Boston, MA 02109
T: + 1 (857) 246-8998

Investor Relations

Maria Kelman
Executive Director, Investor Relations
T: +1-857-362-9635

Transfer Agent

P.O. Box 30170
College Station, TX 77842-3170
T: 1-877-373-6374 (US, Canada, Puerto Rico) or 1-781-575-3100 (non-US)